Amerikanische Gesellschaft für Hirudotherapie

Ministry of Public Health — State of Qatar (Department of Pharmacy and Drug Control)

MoPH Qatar · Qatar · middle east

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Qatar's Ministry of Public Health, Department of Pharmacy and Drug Control — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
middle east
Country
Qatar
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Qatari Law No. 3 of 1983 on the Practice of Pharmacy
  • Qatari Ministry of Public Health Medical Devices Regulations
  • GCC harmonised Drug Registration Procedures (where applicable)

Prescriber Requirements

  • Qatar Council for Healthcare Practitioners (QCHP)–licensed physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Ministry of Public Health registration as applicable; Arabic and English-language labelling. Standard cold-chain conditions.

Import/Export Rules

Ministry of Public Health and Ministry of Municipality / veterinary services import authorisation for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Hamad Medical Corporation (public sector) and private payers determine coverage case-by-case; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. GCC member states share elements of pharmaceutical regulatory harmonisation; whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.